Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Everolimus (Primary) ; Cisplatin
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 11 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
- 11 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
- 11 Jan 2017 Status changed from not yet recruiting to recruiting.